Thalia Therapeutics (LSE:THAT) — Interim results for the six months ended 30 June 2025

0:00 Good afternoon, and welcome to the M4 Pharma PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen.

0:18 The company may not be in a position to answer every question received during the meeting itself. However, company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Nigel Theobold. Good afternoon to you. Good afternoon, and welcome, everybody. And thank you for coming along to listen today to our webinar on our latest interim results. We're just going to give you a a brief flavor of what we're doing this year. And for those some of the others who might be new, a bit of an overview of the company and our new technology, and then how it fits into our strategy into why we see this as a significant investable opportunity for everybody.

1:06 So I'll I'll hand over to Alastair first, who's just gonna walk us through n four and the EVEC technology, and then I'll come back in and talk a little bit more about what we've been up to.

1:16 Thanks, Nigel. Hello, everyone. I'm Alastair Smith, non executive director of n four pharma. Just gonna run through a couple of introductory slides and hand back to Nigel. I think it's probably useful to, you know, to paint a picture of where, you know, where the real value comes from in what we're doing in the Nuvec platform. And, know, the first thing to understand if you're not familiar with the with the company is that we're operating in the RNA therapeutic space, and that's a a very rapidly growing market with expected to be worth about 18,000,000,000 in a couple of years' time. And, you know, the one thing to understand about that market is that the delivery capability is what is lacking. So everyone in that market faces significant challenges in delivering the drugs to the right cells, the right tissues.

2:04 Now N4 Pharma's Nuvec platform is capable, and you you saw an announcement from us last week, is capable of targeting those RNA therapeutics to specific tissues to delivering multiple payloads with one one drug and so on. And that that means we have the opportunity to revolutionize the delivery of RNA therapeutics, not not just for N4 Pharma itself, but by licensing the platform to others to allow third parties to use the the NuVet platform. So our our focus in the near term is on monetizing the NuVet platform in that way through partnerships and in the longer term, really driving value through our own novel RNA therapeutic platform. So we've had a an extra as Nigel will take you through later on. We've had a a very good reporting period the the start of this year, with good positive in vivo data on our n four zero one zero one lead program, which is a inflammatory bowel disease therapy, a dual therapy.

3:09 We successfully raised funds early on in spring, and that's allowed us to really focus on building the data room to support partnering of the of the platform for for licensing deals. So that's our current focus. Let me just if you can go on to the next slide, Nigel, let me go through those key benefits in a little bit more detail, those key benefits that really make Nuveq stand out against the the the platforms that are currently available, such as lipid nanoparticles you may have heard of, viral vectors you may have heard of, that each have their own challenges around immunogenicity and so on as as well as being the the key one. You know, if I was to highlight one thing, as I did on the previous slide, it really is that ability to target the RNA therapeutic, the payload of the delivery platform, to target that to specific cells, tissues, organs, because otherwise, you're obviously getting a a a either a systemic dose or you're delivering it to the wrong tissues.

4:13 For example, example, many of the delivery platforms

4:15 existing now really predominantly go to the liver, and that's not not necessarily what you want to achieve. So targeting the ability to modify the surface of the Nubeq particle so that it will target a specific tissue is a a huge advantage, and it's difficult to do with other platforms. So I'm absolutely certain that's going to be one of the main things that potential partners are interested in in our conversations with them. But just to run through those key benefits systematically, protection, what does that mean? That means that the payload, the RNA, which is a particularly feeble molecule, you know, easily destroyed by enzymes and by pH changes, that that spiky rough surface of the NuVet particle actually endows protection on the RNA therapeutic payload, giving it some resistance to the enzymatic and pH protection, which it would otherwise, you know, suffer from.

5:13 Now that means we can look at oral delivery, which simply isn't possible with other approaches. And that opens up, obviously, a whole new a whole new area of potential therapies of which n four one zero one is an example of an orally delivered therapy for inflammatory bowel disease. And Nigel will say a little bit more about that as we as as we we go along. The second differentiating point is that it's very straightforward to deliver more than one RNA. Once again, n four one zero one delivers an mRNA as well as an s iRNA in a single in a single drug. Now delivering in a controlled way multiple RNAs, again, is extremely difficult with existing platforms. So that that is straightforward to do with the Nuvec system.

6:02 Now all of those things, targeting multiple payloads, protection from breakdown, all of those, obviously, are extremely important, but not if you can't manufacture the, you know, the the end drug. If it's difficult and expensive to manufacture and not stable, then you've got a real problem. And and, you know, the fourth point you'll see down there at the bottom left is that Nuvec is very straightforward to manufacture, both itself as the raw silica nanoparticle, which is the spiky structure, as as well as loading the RNA onto that is very straightforward. You you literally just mix the RNA solution with the Nuvec particles. Stable at room temperature, which is obviously not not usually the case for for delivery systems and very cost effective to manufacture. So these are, you know, these are the ideal properties for an RNA delivery system. And this is why we we strongly believe that we can, you know, revolutionize and become become the platform of choice across the RNA therapeutics industry.

7:10 Nigel? Excellent. Thank you very much, Alastair. So, yeah, just going through this year, Alastair mentioned a few things there. So we we are in a strong financial position. We have reduced our operating loss because we, you know, we are spending very carefully as we go. And the fact that we raised over just over 1,700,000 in early this year, it it just basically has put us in a very strong cash position. So we still have 1,700,000 at the at the at the at the quarter end in June 25. But during that year so what have we what have we done? We've been doing some more work on our n four one zero one, our lead program.

7:57 And as Alastair mentioned, it we've we often had questions. So why why are we looking at why are we looking at IBD? What are we doing with IBD? Because as a market, it's it's very competitive, but it's a very big market. There are lots of people using injectable antibodies at the moment, and there's JAK two inhibitors coming along orally as a as a possible alternative to those. But what we've we've seen, we've seen two things. We we our product, we think, is unique because it it means we can actually target the the the the TNF alpha reduction as required, but without an injectable. And we can also make it oral, which is the JAK inhibitors are although they're oral, they are particularly offset by the fact that they end up all over the body and cause lots of off target issues. So we we believe that product has a significant clinical and commercial potential in its own right. But it also does something else for us. It showcases our technology, our platform in in all its highlights.

8:58 So it protects the the payload. So that means we can deliver it orally, and we've shown that we can get it into the the cells. And this latest work showed because it worked, We showed a good significant reduction in inflammation in our IBD model. We know it gets into the cells. We know it's protected, we know it works. We can do multiple loadings. So we in this case, we've put two different RNA, an mRNA and siRNA on there. We could put two different siRNA. There's various things we can do as we evolve the program, but we can put multiple products on. And very importantly, as Alison mentioned, we're targeting it. So in this instance, we're targeting the macrophage cells with a mannose ligand that's attached to Nuvec. So it's not only a clinically relevant product, it's a showcase for us.

9:43 It's a proof of concept to show everybody, and that's just what we can do. So what we're doing is we're building that data pack around that up. We've also done a lot of work with on targeting. We've as well as the the macrophage manners targeting. We've been going through all the SRI work, and we we just released this week that we've we've we've undiscovered that what the the SRI work has shown is that we can target specific lung cancer cells where they will only work in knock down those the target of choice in those lung cancer cells and not in the other cells. So this opens up a whole host of different opportunities in oncology. So potentially, can combine that with oral and look at delivering a cancer treatment in an orally there in the in the colon or in the gut somewhere.

10:33 So it's a really exciting piece of work that shows that we can actually target specific cells. And we've also just announced as well that we're working with a new group up in the University of Strathclyde called CEMAK. And that's headed up by a lady called Yvonne Perry, who's a world renowned expert in nanoparticle delivery systems, particularly in lipids. So she's going to be taking leading that work, taking our team through the the final data package, looking at how it characterizing it, where it goes in the body, how good it is at endosomal release. But importantly, she's got access to the key lipid systems that other people develop, you know, the the the ones that are used by Moderna and BioNTech.

11:18 So we can have direct comparisons. We've it's been hard for us to get those direct comparisons up to now. Now that we know what Nivet can do and we know it how how it works, we need to be able to show that it works differently. So if lipids struggle to get endosomal release and they can only get one or 2%, and we can get a much bigger number out, we can get directly comparable data, and we'll update the market as we go. It's not just on what we're doing, but also why it's important. So why is each of the bits of work that we're doing important for us positioning our data and allowing us to look at collaborations? And we've also strengthened our leadership and governance team. So I'll go through a little bit more just again, brief highlight of what we've done with the the board. So myself, Luke, and Chris have been around for some time now on the board.

12:07 And recently, we have appointed two new nonexec directors. First was Mike Power from at the end of last year. Mike's US based. He's got a lot of expertise in The US. He brings significant experience of having both built, grown, and exited biotech companies in The USA. We've also then brought on Alastair. And you you know, lot of you will know Alastair as previously at the leading and founding the Avanta Group, and he's got a huge number of years as a public CEO and having grown Avanta to a really strong business. And the the guys have been helping us put together the this new team. So we've appointed Fiona McLaughlin as our new head of r and d, and she's got a lot of expertise in the oncology drug

12:55 development area and has worked with a whole host of different biotech companies. Mark Edbrooke is a really good addition to our science team. He has got he was head of RNA for AZ GSK, so he's got a lot of expertise in working with nucleic acids. And the other thing that he also brings, he's he's been on the other side reviewing lots of people that are presented delivery systems, solutions to them him at the time so he can help guide us through exactly what is needed in order to make that breakthrough for a collaboration. And then to get those collaboration conversations going, we've appointed Simon Bennett as our commercial director. Simon has been in the industry for a scientist as well as a salesperson, and he has worked with a whole host of different clients in this stage from startups to major big pharma. Simon is out there now starting to warm up those conversations so that when our data pack is finally together, we can just present that data back to the people that we're already talking to.

13:54 But also, we not to forget the the CMC side, the chemistry manufacturing and control side. We always this isn't the sexy side. This is the the area that you have to do, but we are doing that, and we're doing that now. Margaret's got a huge number of years of experience in this space. So we need to show that we can make the product, we can do it again, we can do the protocols so that when we hand information and material over to our collaborative partners, it's really easy for them to load the material, test the material, and take those partnership programs forward. So a very strong team now in place, which I think allows us to move into the next phase of our strategy. And I just wanted to put where we are into the valuation curve for large pharma biotechs like us who are platform companies.

14:42 So there are a lot of platform companies that have been through this curve already, and there's lots of different value inflection points as you go through that curve, as you move through and evolve from being just a pure platform company to a biotech company in your own right.

14:57 So companies will start at the beginning looking at their technology, wondering how that works, going through that area of the inception phase, and then they move into the preclinical validation phase, looking at a specific area where they are presenting a particular solution, maybe a product, looking at their platform, showing exactly how it works. And that's very much where we are now with siRNA.

15:22 We have had questions about why is it taking us this long to get this? So I'm gonna preempt that one because this is something that people have asked in other times. We have done a lot of work previously on DNA vaccines. We we had collaboration partnerships. We had a lot of data on generating an immune response, but we we found that we needed to do more formulation work with our DNA vaccine formulations. And then when COVID came along and Pfizer and Moderna did did something really great for the industry, they showed that the RNA therapeutic space will work, but they also showed that for a vaccine delivery, lipid nanoparticles work pretty well. So we were faced with a situation where we we we had a we didn't have a stronger point of difference for for vaccines versus the lipids and the others as we did with RNA therapeutics.

16:15 So a few years back, we switched our strategy to focus on siRNA as the key RNA therapeutic area we want to look at, and we've been doing a lot more work specifically on siRNA. We've been doing the double loading. We've been doing the protection. We've done the oral delivery. So we're really now moving through this preclinical validation phase, and that's what we've raised the funds for at the start of this year. What we then want to do is to move out of that phase into the what we call the evolution phase. That's when you start to see collaborations happen. The platform partnering gets out there. People will take it from preclinical into clinical validation showing that can we actually put into human beings, and then you start to see the valuations really start to grow. When that gives you the opportunity to start thinking about recapitalizing the company, looking to develop our own pipeline further, and expanding products ourselves into phase one, phase two clinical trials. And, again, the value is moves up through there until finally, you move into some form of exit at a billion dollar plus.

17:16 And these are the sort of numbers. And we're not just making these numbers up. On our on our website, we've got a few case studies on there, but just sort of talk you through one here. You can look at some of the others on there or you can get them from our hub.

17:29 But Dicerna are a really interesting company. They were founded back in 2017. And I'm gonna use, I think, a quite harsh word for that. I'm gonna they just used a fatty acid modification system to deliver RNA. They started out delivering it to liver, but then they look at it evolving it to other tissues like muscle, heart, and the retina. And they were able to raise significant early funds, move through their evolution phase, raising another 100,000,000. So in total, they raised around a 115,000,000 as long alongside some grants as well. And, ultimately, just two years ago, they were acquired in a billion dollar deal by Novartis. So they had one lead program, which was a product targeting a very rare disease called Charcot Marie Tooth disease. They had orphan drug status for that. But the key takeaways you can see from this is that the whole growth was just driven by their proprietary RNA platform that they called. We call ours Nuvec.

18:30 Ours is not a lipid system. It's a silica based system. But then moving into pipeline expansion into other tissues other than the liver allowed them to expand their program and ultimately get acquired. And the reason they were acquired is because of Novartis' interest in that Falcon delivery platform. And and this is a classic case study of how platform companies evolve. And as I said, there's others on there. There's Arrow Bioethetics out there. There's a few other companies that we've put on our website that shows you the sort of evolution that companies go through. So we believe there's a really strong investment case in n four pharma. We have a proprietary RNA delivery platform that we think is transformation, and it can become the next generation system for nanoparticle system for RNA therapeutic development.

19:24 We're we're early we we've validated our early proof of concept data so that derisks the platform a lot and add that to all the vaccine work that we did in the past, then we can show that we can deliver RNA orally. And, you know, we we have shown this. We've got it into the body, into the the gut, into the colon, and it's had a systemic reduction in inflammation, which has continued over a period of time. And we're looking to evolve that into further work in the future. We we have an experienced leadership team. So we've got a very clear, funding and partnership pathway that we're going down, and I'll just talk you through that. And it's in a compelling high growth market opportunity of RNA therapeutics, Whereas, Alisa says, although it's a high growth, high value market, all people operating here need delivery systems. Every time you go to any conference, any meeting, everybody's talking about the concept of how do you deliver RNA because without delivery system, the RNA will not work.

20:23 And also, it's something that's I think this is really important for retail investors. If you think back to that curve where companies are going through and getting to the sort of 500,000,000 stage and ultimately selling for a billion plus. Typically, the VCs fund all those early stages, and that was definitely the case with Dicerna. So they would they sum they will come to market round about the end of that phase four when they're coming into the the the moving their own different pipelines of assets at quite high valuations. So retail investors just do not get the chance to get involved in the biotech companies in the early phase. They typically can only invest in them once they come to market. And then if you go from 500,000,000,000 to a billion or a billion and a half, you're looking at a two to three times multiple. The retail investors can get involved with us now because we're at early stage, we're on the market, and they're taking part in the VC phase of of of our growth, getting significantly higher returns from those low valuations of $2,030,000,000 up to 500,000,000 plus.

21:23 So we we're delighted to be offering retail investors the chance to participate in something that only really the venture capital companies get involved in. So, hopefully, that gives you an overview of n four and our strategy. And with we'll just move into a few questions and answers. That's great. Nigel, Alastair, thank you very much indeed for your presentation. Ladies and gentlemen, please do continue to submit your questions using the q and a tab situated on the top right corner of your screen. While the company take a few moments to view those questions submitted today, I would like to remind you that a recording of this presentation, along with a copy of the slides and the published Q and A can be accessed via investor dashboard. Nigel Alister, as you can see, we have received a number of questions throughout today's presentation.

22:10 If I may now hand back to you kindly ask you to read out the questions where appropriate to do so, and I'll pick up from you both at the end. Thank you. Excellent. Thank you very much. So I have a couple submitted. I'll just the the re they're very similar. So one was that we said that the focus is on building a commercial data package. Is this sufficient to secure the first licensing licensing or partnership agreement? And then Alex has also asked, what what milestones have we got to reach before we can secure the first licensing or co development partner for Nuvec? Now I'll I'll just read so we believe that by completing that data pack that we're doing on our, you know, our platform and then presenting that to the partners, that will be sufficient interest to start getting a collaboration agreement.

22:55 Whether that means they initially will invest and license that from us or they might they might say, look, we want to do some preliminary work. So there may be a period of collaboration where we're working together, looking at a specific area before that when they ultimately lead her to a license agreement. So I honestly believe that those milestones are are there. We can get some collaborations, and, hopefully, that will start to we we get out there in early twenty six when we start to get of that data platform together. I don't know, Alastair, if you want to to build on that a bit more. Yeah. Yeah. No. I mean, you you also answered the question. I I would I would say we should really stress the point because this is not doing science for academics or academic sake. You know? This is not science for science's sake.

23:42 I cannot stress how important having a comprehensive and robust commercial data room is to doing license deals. You know, that those data have to withstand detailed due diligence. Nobody is gonna commit time and cost to a, you know, to licensing a a platform from us, the Nuvec platform, and undertake work themselves if they're not completely satisfied that it can deliver, you know, what they want. And there is there is already a wealth of data, but there isn't a comprehensive, well organized systematic data room. And that's what we're putting the you know, i's and crossing the t's over the coming coming twelve months or so. So it it really is absolutely essential. You know, we we will aim to have, you know, everything we can think that we need. Need. I can guarantee somebody else will ask for something that we don't have. That is always the case, but we will have, you know, everything that is necessary to be able to get deals over the line. I would just add one more thing that all of the work we're doing, because we're also doing a lot of the work on n four one zero one, you know, a lot of that is gonna be highly relevant for our regulatory submissions in future. So we're killing two birds with one stone and being as efficient as we possibly can with resources.

25:05 Thank you, Allison. Yeah. And building on from that, another question that's linked to that from Martin. What what are the next specific data points or readouts investors should expect from the the CMEC collaboration on and on what timeline? I don't mind taking that one, Nigel, if you want. Absolutely. Yeah. Okay. So CMEC is not CMC as well. Okay? So just to make that point, a very significant very significant part of what we're doing is related to the CMC, the the manufacturing, the process development opt optimization, and the stability. So that now, again, again, just just to I I know I sound like I'm a broken record, but if you're a partner and you want to explore the use of Nuvec, you absolutely have to know that there is a reproducible, manufacturing process in place because, otherwise, it's pointless doing the, you know, the r and d if ultimately you can't manufacture the damn stuff. So, you know, we we we are putting a lot of effort into CMC, and that's out with Seamac.

26:06 And CMEC is doing the we'll do the the biology, if you like, the biology r and d. So, you know, that's everything ranging from loading of particles with with multiple RNAs and looking at the stability characterizing those. So, you know, what what processes are required to control the loading of two or three RNAs onto a single NuVec particle and how does that affect stability and so on? Target engagement is really important. So targeting and target engagement. Yeah. We talked about the importance of that. We've got several examples now. Nigel's mentioned two, the mannose targeting of macrophages and using a peptide to target non small cell lung cancer cells with in our collaboration with SRI.

26:57 We want to do a couple more examples that'll be very relevant to what we know people are interested in from an RNA therapeutics perspective. So targeting and target engagement, that work will be done in with Yvonne. Then there's work packages around biodistribution, for example. We have some, but I think it's fair to say limited data describing the biodistribution of untargeted and targeted Nuvaic particles. So that's another very important one. Nigel's mentioned endosomal release. So escape is I mean, very briefly, I'm not to go into too much of the detailed biology. One once the Nuvec particle has got into into the cell, you know, the targeted cell, it goes in as part of what's called an endosome. It doesn't matter what that is, but it goes in in in something called an endosome. And it's gotta get out of that endosome in order for the RNA to then go and have its, you know, its effects within the cell and cause the cell to change the protein expression in some way. And that's what's called endosomal escape or endosomal release.

28:06 We we know that the proportion of RNA getting getting into into cells through lipid nanoparticles and viral vectors, the proportion that actually escape the endosome and have an effect is very low, single digit percent. So so being able to demonstrate that we get a higher level of endosomal escape, endosomal release will be, you know, very significant because it clearly reduces the amount of drug you have to get to give to people if more actually gets to the the sites of action. And then finally, the other you're you're asking specifics, so I'm giving you specifics. The other big work package is further in vivo proof of concept efficacy data in in an inflammatory bowel disease mouse model. So building on the data we already have and going further and into greater depth for our lead program, m four one zero one. And all of that will be done at Strathclyde, and CMC will be done separately separately with contract partners.

29:07 Yeah. Yeah. Thank you. And just to build on that, the because that was another separate question that we're asked about what next on n four one zero one, so that follows very nicely. So the the the the prework that we'll be doing will be done at the stratified, and we'll be looking at, like I the whole formulation, making sure we get all the protocols right for doing that loading. And then we will be looking to do a larger, more extensive in vivo IBD model. And we we won't be doing that at the in the academic institution. We'll be doing that in a a a full fledged contract research organization that's got lot of expertise in working with that preclinical model. So we'll have a full set of preclinical data showing efficacy of our product in an in vivo setting with a very you know, have a much larger, well tested model. So that will happen after we've completed all of the characterization work at Strathclyde.

30:09 There was also another question following the the talk about SRA and what next in the steps to validate a new vaccine for oncology. So as we said, you know, we've shown that we can target specific non small lung cancer cells. Really, what we need to do now is we either need to look at different cells, and there could be a range of different cells that we look at to show that the targeting happens again and again and again. Or we go down into an in vivo environment showing that actually as well as targeting that, we can target it in the in the efficacious animal model. And that's something that we're talking to SRI with at the moment about which is the right path to go down for that work. But we can begin to grow and look at that. But it it could be that our team decide, actually, we're looking at an area that in oncology that might be more useful combining things together. So a classic example would be looking at an orally delivered oncology drug to treat a specific cancer in the gut or in the upper colon.

31:09 There's a lot more work we need to do on scoping that out, but it shows the sort of potential of things that we can do. And we will be updating you more as as our ideas progress and get screened. And that will be part of the early stage work that we need to do as a company to move out of that next phase into the the the pre the preclinical validation of one area into an expanded opportunity of pipeline products, albeit at at earlier stage. Hopefully, that's answered those. Yeah. Linked in that. How strong is the patent protection around Nuvec? Good question. We have a we have a patent for the Nuvec system. It's basically the matter of composition of the particle. And what that means, it's the shape, it's the structure, it's everything to do with that spiky mesoporous silicon nanoparticle.

31:58 So nobody can do a mesoporous silicon nanoparticle with spikes on like that that that would be infringing the patent. What we that that lasts till into the mid late thirties. So what we're doing is we are building on a suite of other patents around extending that protection. So we've already filed one around our IBD program. We can't say too much about that at the moment because we're in the the non publication stage, but when that's published, people will be able to see a lot more about that. But also, when we start to partner with people so we take NuVet, we combine that with someone's siRNA. Maybe they're working in the field of pancreatic cancer. There will be new patents that will be able to be filed there in conjunction. There'll be new patents that we can possibly file in those areas that we can then take to potential licensing partners. So we'll be building a suite of therapeutic and product specific patents using NuVet platform that move beyond from the just the particle itself to the particle in specific areas. And as we there's lots of opportunities to how we can go down there. So we have strong pattern protection, but we we can also build on that and make that last a lot, lot longer.

33:14 So we've all the other we've sort of answered all those questions that have been submitted. So if if nobody's got any other questions that they want they've always got one now. We got another few seconds to put it in. Otherwise, we'll draw this to a close. Just give it another ten, twenty seconds, Nigel. Yep. Okay. So I think I think that will be it for the people attending. So I'll hand back to Georgie. So do we close before I hand back? Yes, please, Nigel. Just just thank everybody again for your for your time to coming along, listen to our interim results. The results are now up on the website so you can have a good read of them.

34:05 As I say, please do take the opportunity to sign up to our investor hub. We put lots of information on our hub, on our invest on our website, on the investor section. As as I mentioned, we have put other case studies up there. We will be putting more information out to people about where to find them and and to give people a reason why you should come along and invest in n four pharma. So, hopefully, today's giving you a bit of an update of where we where we are this year, what we've been doing, and what our plans are for the for the next year and beyond. Thank you very much, everybody. Thank you. Thank you. That's great, Nigel. Alastair, thank you very much indeed for updating investors today. Could I please ask investors not to close this session as you will now be automatically redirected to provide your feedback in order that the Board can better understand your views and expectations.

34:53 This will only take a few moments to complete, and I'm sure will be greatly valued by the company. On behalf of the management team of M4 Pharma PLC, we would like to thank you for attending today's presentation, and good afternoon to you all. Thank you.